Become a Cannaray CBD Investor
Cannaray is a leading European cannabis company spanning both medical THC and CBD wellness brands.
We are on a mission to heal ourselves from within and help pave the way for our friends and families. We believe in creating products good enough for ourselves as well as treating our customers like family.
Cannaray CBD is the company’s flagship CBD wellness brand – founded to make CBD easy and accessible for millions of new people. Its product range includes CBD Oil Drops for day and night, Capsules, Gummies and Muscle Balm. All Cannaray CBD products are formulated to be effective and enjoyable to use, triple-lab-tested for purity, and are packaged in the modern, bright, and optimistic Cannaray brand colours.
Meet the Cannaray Team
Cannaray’s team brings a new level of professionalism to the cannabis industry with expertise covering IPOs, building companies through consolidation, life sciences, media, consumer and retail, all complementary backgrounds to create tangible shareholder value in medical cannabis and retail CBD.
Chief Executive Officer
Expertise in starting and building businesses. Scott has played a key role as an executive in building five companies or divisions of larger companies from concept to high value including trade sales and IPO. Scott has built a company from two patents to a NASDAQ listing (ticker: XBIO) and has also built a dialysis clinic chain from scratch to the UK’s second-largest private provider of dialysis services. He has assisted in building National Medical Care’s fledging international business from $15M to $350M in revenues. Scott also built a healthcare corporate finance practice from scratch to 35 professionals globally.
Highly experienced, successful chairman in NED roles and former CEO positions, across various food manufacturing sectors, in blue-chip corporates and private equity-backed businesses, with particular skills in deal-making, turnarounds and transformation, and building great teams with specific focus on executional excellence, meeting or exceeding the needs of all stakeholders, particularly value creation for shareholders. Chairman/CEO of companies with transaction values of $1.5B.
Chief Financial Officer
Experienced CFO, qualified Chartered Accountant and board-level director with a demonstrated history of developing and growing service businesses leading to improved shareholder value. Numerous M&A activities including the successful exit of a private equity-owned business. Developed significant improvements in management reporting, controls and strong financial reporting acting as a business partner for the development of the organisations. Lead several refinancings with strong banking relationship experience.
Chief Business Officer
Investor and entrepreneur with experience in institutional investment and trading, international real estate investment, and private market investment. Joshua worked for Highbridge Capital Management for over a decade in London and New York and established the European trading desk for the StatArb team in London. He started angel investing in 2010 and cannabis has been his investment focus since early 2017 in both the public and private markets.
Chief Marketing Officer
Experienced CMO with successful track record of building premium brands within major FMCG organisations, including Reckitt Benckiser, Bacardi and innocent drinks. Sectors include OTC Healthcare, Premium Alcoholic Spirits, Soft drinks, Laundry Care and Personal Care. Skilled at the full marketing mix including brand building, innovation, advertising and media, digital and social. Geographic experience includes global leadership roles and local assignments based in Europe, Middle East & Africa and China.
Our Non-Executive Board of Directors
Strengthening Cannaray’s offering is a world-class Board of Directors covering industry-specific expertise in listing and running public companies, life sciences, financial, legal, media and the cannabis industry.
Chris Sullivan, Ex Deputy Group CEO of RBS and Ex CEO Corporate Banking of Santander
Sir Nigel Knowles, Ex Global Co-Chairman of DLA Piper and now Chairman of DWF Group PLC
Michael Freedman, CEO of Alchemy Media and an entrepreneur in the USA cannabis sector
Andrew Garden, Ex MD of Proctor & Gamble - Europe, and FMCG Expert
Gregor Zorn, Cannaray's Chief Science Officer
Our Scientific Advisory Board
The SAB is comprised of key opinion leaders covering the four approved indications to treat with medical cannabis in the UK (chemotherapy-induced nausea and vomiting, epilepsy, multiple sclerosis, chronic pain).
Dr Benjamin Thomas, Pain Specialist
Dr David Moorhouse, General Neurologist
Dr Daniela Tonucci, Pain Specialist
Dr Balu Pitchiah, Consultant Psychiatrist
Dr Tom Jenkins, Neurologist
Dr Emily Collins, Palliative Medicine
Dr Andrew Aswani, Intensive Care and Anesthesiologist
Dr Peter Laing, Drug Delivery Scientific Expert
Simon Tallett, Pharmacist
Richard Davey, Pharmaceutical Distribution